PTGER2 and myeloid sarcoma: Kihara et al. (2009) proposed that at least EP1/EP2/EP4 receptors may participate in the PGE2-elicited MS pathogenesis in various cell types, and the suppression of mPGES-1 activity by specific inhibitor may be a potential treatment against MS in humans.